showed that in advanced NSCLC, patients with four genetic IFN-γ+ signatures (interferon γ, CD274, LAG3, and CXCL9) had longer median OS (18.1-22.7m vs 6.5-7.7m) and six-fold higher objective remission rate (ORR) regardless of the immunohistochemical (IHC) PD-L1 status (83). This evidence concerns the gene IFNG and non-small cell lung carcinoma.